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ABSTRACT
Introduction Survival after critical illness has noticeably 
improved over the last decades due to advances in critical 
care medicine. Besides, there is an increasing number of 
elderly patients with chronic diseases being treated in the 
intensive care unit (ICU). More than half of the survivors 
of critical illness suffer from medium- term or long- term 
cognitive, psychological and/or physical impairments 
after ICU discharge, which is recognised as post- intensive 
care syndrome (PICS). There are evidence- based and 
consensus- based quality indicators (QIs) in intensive care 
medicine, which have a positive influence on patients’ 
long- term outcomes if adhered to.
Methods and analysis The protocol of a multicentre, 
pragmatic, stepped wedge cluster randomised controlled, 
quality improvement trial is presented. During 3 predefined 
steps, 12 academic hospitals in Berlin and Brandenburg, 
Germany, are randomly selected to move in a one- way 
crossover from the control to the intervention condition. 
After a multifactorial training programme on QIs and 
clinical outcomes for site personnel, ICUs will receive 
an adapted, interprofessional protocol for a complex 
telehealth intervention comprising of daily telemedical 
rounds at ICU. The targeted sample size is 1431 patients. 
The primary objective of this trial is to evaluate the 
effectiveness of the intervention on the adherence to eight 
QIs daily measured during the patient’s ICU stay, compared 
with standard of care. Furthermore, the impact on long- 
term recovery such as PICS- related, patient- centred 
outcomes including health- related quality of life, mental 
health, clinical assessments of cognition and physical 
function, all- cause mortality and cost- effectiveness 3 and 
6 months after ICU discharge will be evaluated.
Ethics and dissemination This protocol was approved by 
the ethics committee of the Charité—Universitätsmedizin, 
Berlin, Germany (EA1/006/18). The results will be 
published in a peer- reviewed scientific journal and 
presented at international conferences. Study findings will 
also be disseminated via the website ( www. eric- projekt. 
net).
Trial registration number  ClinicalTrials. gov Registry 
(NCT03671447).
INTRODUCTION
There is substantial heterogeneity in the 
process of critical care worldwide.1 With 
more than 2.1 million critical care cases 
(25/1000) per year, Germany has one of 
Strengths and limitations of this study
 ► Telemedicine- based care potentially improves the 
adherence to quality indicators in intensive care 
medicine, which accelerate patient recovery and 
improve long- term outcomes after critical illness.
 ► Enhanced Recovery after Intensive Care (ERIC) is 
the first large- scale cluster randomised controlled 
trial to be carried out in intensive care units (ICUs) 
in Berlin and Brandenburg, Germany, comparing 
the clinical and cost- effectiveness of a telehealth- 
based quality improvement intervention to standard 
of care.
 ► By employing a stepped wedge design, this quality 
improvement study will allow each cluster to act as 
its own control preserving the internal validity of the 
study, and has a potential for confounding by under-
lying secular trends.
 ► The nature of the intervention does not allow blinding 
of study personnel and eligible patients at ICUs.
 ► ERIC allows for a comprehensive evaluation from 
the patient’s perspective, healthcare staff and health 
economics and to assess its suitability to become 
standard of care.
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the most dense critical care environments in devel-
oped countries.2 Over the last two decades, increased 
life expectancy, demographic changes and progress 
in treatment have resulted in increased survival, thus, 
resulting in trajectories typical for this new cohort of 
intensive care unit (ICU) survivors.3 These trajectories 
are characterised by impairments including mental 
illness (ie, anxiety, post- traumatic stress disorder and 
depression), neurocognitive degeneration and neuro-
muscular end organ failure resulting in conditions 
such as long- term ventilation.4–8 These long- term 
consequences are summarised as post- intensive care 
syndrome (PICS).9 10 Aside from PICS, a subcohort 
of ICU patients shows ‘chronic critical illness’ (CCI), 
characterised as a state of chronic dependence on 
organ support. Nowadays, these patients receive care 
in very heterogeneous settings, from rehabilitation 
centres to long- term acute care facilities or nursing 
homes. There are evidence- based strategies to reduce 
the PICS/CCI burden. These include, for example, 
the prevention of delirium, the preference of no or 
light sedation over heavy sedation, the conduction 
of spontaneous breathing trials for timely liberation 
from the ventilator4 11–17 and the use of quality indi-
cators (QIs).
The German Interdisciplinary Association of 
Intensive Care and Emergency Medicine (DIVI) has 
summarised 10 QIs for intensive care treatment as the 
‘German QIs of intensive care’, with the first version 
established in 2010.18 This set of 10 QIs reflects 
consensus- based strategies to improve quality of acute 
ICU care and, thus, can reduce PICS/CCI burden. 
For instance, if patients are frequently assessed and 
consequently treated for delirium, cognitive outcomes 
might improve.4 Yet, the adherence to these QIs is 
comparatively low and comprehensive implementa-
tion strategies are often lacking.19 20 QIs pertain to 
one or more of the three domains structure, process 
or outcome of quality of care.21 In QI development, 
areas of clinical practice need to be identified where 
evidence- based, best practice diverts from what is 
actually delivered to patients. Then, measurable key 
performance indicators are defined serving as surro-
gates for the level of implementation of the respective 
single QI. These must be accepted by the clinical team 
and, in the next step, implemented in daily practice 
to ultimately improve patient outcomes.18 As such, 
QIs can be used to align the allocation of healthcare 
resources for the improvement of patient outcomes 
within acute care as well as in the post- ICU period.
Telemedicine in critical care can be used as a vehicle 
to transport content and quality to medical settings 
and has already become a cornerstone in care settings 
with reduced access to intensive care specialists.22 23 It 
typically consists of a telemedical cockpit and a remote 
site, which share an audiovisual connection and health 
data to various degrees (depending on the applied care 
model).24 Several studies and meta- analyses revealed a 
significant reduction in ICU mortality and lengths of stay 
at ICU by telemedicine applications.25–27 Nevertheless, 
data on alternative aspects of the effectiveness of ICU 
telemedicine programmes are limited and conflicting.28 29 
Building on this evidence, there exists, to our best knowl-
edge, no randomised controlled trial investigating 
whether a virtual care network is capable of increasing 
quality of care and decreasing functional impairment of 
ICU survivors.
To fill this evidence gap, the quality improvement 
trial Enhanced Recovery after Intensive Care (ERIC) 
was initiated. This project is funded by the German 
Innovation Fund (‘New Forms of Care’) coordinated 
by the Innovation Committee of the Federal Joint 
Committee (grant number 01NVF16011; https://
www. g- ba. de/ english/).30
METHODS AND ANALYSIS
This trial protocol is presented in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) statement31 32 (see online 
supplemental file 1) and also considers the Consolidated 
Standards of Reporting Trials (CONSORT) reporting 
guideline for stepped wedge cluster randomised trials 
(SW- CRT),33 34 the Standards for Quality Improvement 
Reporting Excellence (SQUIRE) reporting guideline35 
and the Template for Intervention Description and Repli-
cation (TIDieR) checklist.36 The project’s webpage ( www. 
eric- projekt. net; in German) provides an overview for 
clinicians, patients and their relatives. 37
Aim and objectives
This trial aims to demonstrate the clinical effectiveness 
of a multifaceted quality improvement intervention medi-
ated by a critical care telemedicine service at ICU. The 
project with a target recruitment goal of 1431 patients in 
total has the following primary objective:
 ► To evaluate the benefit of a complex behavioural and 
telemedicine- based intervention on the adherence to 
evidence- based, national QIs daily assessed during the 
patient’s ICU stay.38
Secondary objectives are:
 ► To evaluate whether the intervention improves 
long- term core outcomes including overall survival, 
health- related quality of life, and other (PICS- related) 
patient- centred outcomes concerning mental health, 
cognition and physical function of ICU survivors 3 
and 6 months post- ICU discharge when compared 
with standard care.
 ► To estimate, in a health economic analysis along-
side the main trial, the cost- effectiveness during the 
6 month post- ICU follow- up for patients exposed 
to the intervention versus to the control condition 
at ICU. We aim to assess whether the intervention 
imposes lower costs and care needs than routine 
practice, for example, by reducing the proportion of 
patients discharged ventilated from ICU.
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Study design and setting
ERIC is a national, large- scale, multicentre, pragmatic, 
cluster randomised controlled trial with an open 
cohort stepped wedge design with continuous recruit-
ment.39 The study will be conducted in adult critical 
care units of hospitals located in the metropolitan 
area of Berlin and the rural area of the surrounding 
federal state Brandenburg with a population of 
about 6 million inhabitants in total. The study area 
has approximately 150 000 ICU admissions per year 
(Gesundheitsberichterstattung (GBE)–Bund health 
data40). During three predefined steps over the study 
period of 25 months (first patient in to last patient 
out), which includes a 6 month post- ICU follow- up at 
the patient level, participating hospital facilities are 
randomly selected to transition from the control to 
the multicomponent intervention condition. Once a 
cluster crosses over to the intervention, it will remain 
exposed to the intervention for the remaining dura-
tion of the study. After the last cluster has crossed over 
and has fully transitioned to the intervention, there 
will be a final 7- month period during which all ICUs 
will be fully exposed (see figure 1). This trial requires 
that all participating hospitals begin the control phase 
of the trial when the data collection period begins.
Site selection
Hospitals defined as study sites are eligible to participate 
if they are able to commit to the following criteria at the 
institutional level:
 ► Providing adult critical care units.
 ► Located in the Berlin/Brandenburg metropolitan 
region.
 ► Adherence to general legal obligations to participate 
in the study funded by the German Innovation Fund 
and participation in the respective contracts (which 
includes a cooperation agreement with Charité—
Universitätsmedizin Berlin).
 ► Adherence to cluster randomisation.
Trial sites were recruited from the set of hospital facil-
ities according to their letter- of- intent written during 
the project application ensuring that recruitment, data 
collection and delivery of the telemedicine- based inter-
vention are feasible. The defined randomisation units, 
that is, clusters comprising of one to three ICUs, are 
geographically and organisationally separated, which 
prevents workforce movements between clusters, and 
thus, intervention contamination.
Patient population and eligibility criteria
Patients admitted to the ICU at the participating site will 
be routinely screened against the following eligibility 
criteria:
Inclusion criteria at the participant level
 ► Age 18 years or greater.
 ► Expected to receive treatment in a mixed, medical or 
surgical ICU connected to the project for more than 
24 hours.
 ► Coverage by a German statutory health insurance 
company.
Figure 1 Schematic illustration of the staggered rollout process and timeline applied in the ERIC project (after the decision 
to extend recruitment, including postponement of third crossover date (indicated as vertical dashed line)). Blue areas indicate 
intervention stage (telemedicine), grey areas control stage and the unshaded area indicates the post- ICU phase (displayed 
after LPFV). In each sequence group, a 3- month transition period at the end of the control condition is defined. Follow- up 
assessments (secondary outcomes) on the patient level 3 and 6 months after index ICU stay. Randomisation of 12 units 
occurred at a single time point prior to patient enrolment; one cluster of sequence group 3 withdrew informed consent prior to 
start of recruitment. ERIC, Enhanced Recovery after Intensive Care; FPFV, first patient first visit; ICU, intensive care unit; LPF(L)
V, last patient first (last) visit.
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 ► Written informed consent of patient or legal 
representative.
Exclusion criteria at the participant level
 ► Age less than 18 years.
If a study patient is readmitted to a participating ICU 
at a later date, the same eligibility criteria will be applied 
and the patient can be enrolled on multiple occasions.
Patient recruitment and informed consent model
Prior to trial commencement, participating sites have 
to provide informed consent on an institutional level. 
Due to the open cohort design, patients are recruited in 
continuous time as they become eligible, that is, usually at 
ICU admission, and most of them are exposed for a short 
time.41 Patients will be identified and screened for eligi-
bility by the local team in the ICU, which has been trained 
by the central study coordination team of the Charité 
(consortium leader; for details concerning the structure 
of the ERIC consortium see online supplemental file 2). 
Written informed consent is obtained by the patient or 
the legal representative if the patient is unable to consent.
Randomisation, allocation concealment and masking
Due to the stepped wedge design, hospitals defined as 
clusters are randomised to receive the experimental 
intervention at different preplanned crossover dates 
(‘steps’), and all clusters receive it (figure 1). Prior to 
trial commencement, 12 sites that have provided a letter 
of intent to be involved in the study will be randomised. 
The independent trial statistician contemporaneously 
randomised the hospital sites to one of three sequence 
groups using a computer- generated algorithm (nQuery 
Advisor V.7; simple unrestricted allocation and fixed 
block size). Concealment of the crossover date assign-
ment from sites and the research team is not possible 
due to the inevitable planning of the preceding training 
period for ICU personnel. Patients will generally be aware 
of the condition they are exposed to (depending on their 
health condition during ICU stay). However, patients 
(and their proxies) will be unaware of the allocation 
sequence, that is, those not yet receiving the intervention 
will not be aware of the time at which the intervention is 
implemented at the treating ICU. By nature of the trial 
design and the intervention, it is not possible to blind the 
study personnel at ICUs. After ICU discharge, interviewer 
staff, healthcare providers (eg, at rehabilitation facilities) 
and general practitioners conducting follow- up assess-
ments may be aware of the treatment condition (due to 
access to medical records), and therefore cannot be kept 
blinded. Independent data analysts are not involved in 
outcome assessment; they will be handed the final data-
sets for evaluation by the consortium leader in order to 
perform preplanned statistical analyses.
Although several outcome assessors including data 
analysts will not be blinded, we do not expect a high risk 
of ascertainment bias to influence the treatment effect 
for objective outcomes.
Treatment conditions and implementation of the intervention
Figure 2 displays a schematic representation of the pillars 
of the ERIC intervention and underlying mechanisms to 
improve quality of critical care.
Intervention condition: telemedicine
A health- related behavioural, quality improvement inter-
vention comprising of the following two core components 
will be implemented at the institutional level:
1. Structured daily, telemedical cart- based ward rounds 
will be conducted, guided by QIs in intensive care 
medicine (V.2017 published by the DIVI38) in order to 
Figure 2 The pillars of the ERIC intervention: an integrated approach to critical care and causal pathways. Due to the 
complexity of the comprehensive ICU telemedicine intervention with multiple co- dependent components, all pillars need to be 
effectively implemented to be successful. *Behavioural changes include process- related factors: planning and coordination 
of measures, risk- benefit evaluation, responsibilities and roles. Cultural barriers: lack of mobility culture, staff knowledge and 
critical care expertise, or prioritisation of therapeutic concepts. †Direct mechanisms are the mechanisms that might influence 
the QI adherence without a behavioural change; the identification of structural barriers that result in limitations (eg, no availability 
of an electronic medical record so far) might have an influence on the QI documentation and, thus, QI adherence. ERIC, 
Enhanced Recovery after Intensive Care; ICU, intensive care unit; QI, quality indicator.
 on O









pen: first published as 10.1136/bm






5Adrion C, et al. BMJ Open 2020;10:e036096. doi:10.1136/bmjopen-2019-036096
Open access
assess patient- individual QI- related performance mea-
sures. QI visits will be led by a specialised ICU consul-
tant and a critical care- trained nurse working in the 
telemedical cockpit (tele- ICU, located at the cluster 
Charité at the site of the consortium leader) and at-
tended by the concomitant treating physician and the 
bedside nurse at the remote ICU. This telehealth ap-
proach involves an interactive and secure two- way au-
diovisual communication at the bedside of the patient 
and face- to- face dialogue during delivery of healthcare 
between the tele- ICU and local care provider. This pro-
cedure is based on remote video visualisation of the 
patient and their monitoring devices by means of the 
telemedical cart serving as access device.
Each round entails the discussion of all QIs (table 1) 
in a step- by- step approach discussion, for example, se-
dation, ventilator settings and antibiotics. QI- related 
criteria are subsequently assessed based on informa-
tion obtained and documented by the tele- ICU con-
sultant during daily telemedical ward rounds and on 
medical records at the remote ICU. Beyond mere QI 
assessment, the tele- ICU consultant can provide addi-
tional advice concerning treatment plans to remote 
ICU physicians.
2. A 24/7 on- call service staffed with a board- certified 
critical care specialist will be provided by the telemed-
ical cockpit to ensure the coverage of acute medical is-
sues on demand and easy access to high- quality ‘virtual 
care’ in the local treating ICU.
The main features of the tele- ICU and its equipment 
together with a photograph of the telemedical cart 
(manufacturer: InTouch Technologies, USA) used in the 
local patient rooms are provided in the online supple-
mental file 3 following the TIDieR checklist.36
Control condition: usual ICU care
While delivering the control condition, ICUs are provided 
with no special instruction in the care of their patients 
and treatment is considered to be ‘usual care’ according 
to local standards, that is, the status quo provided by the 
cluster’s ICU before the randomised start of the interven-
tion, with treatment at the discretion of the treating clini-
cian. In particular, no telemedicine- based support will be 
provided during the daily bedside ward rounds. Hence, 
assessment of QI adherence in the control phase is based 
on examination of medical records regarding QI- related 
parameters (table 1).
Preceding training activities and implementation of the intervention
A structured multicomponent training programme will 
be provided to all hospitals within a sequence group 
taking place during the last 3 months before the cross-
over date representing a transition phase.
The training is delivered as a blended- learning 
concept with (1) an e- learning course for each QI (ERIC 
e- learning platform accessible at https:// best- edx. charite. 
de), (2) a simulation- based training and (3) an on- the- job 
training to make sure the local ICU staff is trained in the 
use of the telemedical cart. Not the whole ICU team at 
Table 1 Consensus- based set of quality indicators in intensive care for Germany (third edition 2017, see Kumpf et al38) 
applied for the definition of the binary primary outcomes
Indicator no. Description of QIs Criteria for QI adherence
QI I Daily multiprofessional and interdisciplinary clinical 
visits with documentation of daily goals
Daily medical round with a multiprofessional team and specified goals
QI II Management of sedation, analgesia and delirium Assessment of (1) level of sedation, (2) delirium and (3) level of pain with 
appropriate scoring tools
QI III Patient- adapted ventilation In case of mechanical ventilation, application of low tidal volume, 
adequate ventilation pressures
QI IV Early weaning from invasive ventilation Daily evaluation of weaning potential and standardised spontaneous 
breathing trials
QI V* Monitoring the measures for the prevention of 
infection
N/A
QI VI Measures for infection management Early, empirical anti- infective therapy; early microbiological testing; 
avoidance of unnecessary anti- infective therapy; therapeutic drug 
monitoring
QI VII Early enteral nutrition Early feeding with patient- specific calorie goals; application of 50% of set 
calorie goal within first 48 hours of ICU admission
QI VIII Documentation of structured patient and family 
communication
Documented communication with patient’s family or proxy; adequate 
content including patient's personal preferences
QI IX Early mobilisation Early mobilisation within first 72 hours of ICU admission and then daily 
physiotherapy
QI X* Direction of the intensive care unit N/A
*Quality indicator (QI) V and QI X are not specified as primary efficacy outcomes since they are not assessed on a patient- level during daily QI visits 
and do not enable estimation of an interpretable effect of the intervention.
ICU, intensive care unit; N/A, not applicable.
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the participating site will be trained, but local experts 
(physicians and nurses) can operate as multiplicators 
within the team. Prior to the training period, ICUs are 
highly encouraged to consider a medical peer review as 
a standardised tool for continuous quality improvement 
in intensive care medicine, which was developed by the 
German Medical Association (based on the conceptual 
framework of the Plan- Do- Study- Act cycle)42). These peer 
reviews conducted during multiple visits by colleagues 
promote the exchange of experience between professions 
and disciplines at ICU and focus on the systematic evalu-
ation of the quality of an ICU’s structure, its processes 
and outcome to secure the sustainability of the planned 
change processes in patient care.43–45
Adherence to the intervention
After the crossover date, the adherence to the interven-
tion condition delivered by the ICU is monitored by the 
tele- ICU team. Tele- ICU consultants will ensure that every 
patient treated on intervention condition is rounded on 
daily. The login times to the audiovisual communication 
are monitored by a distinct fleet management system 
resulting in an anonymous monthly performance report 
and show the connection times that enable to draw 
conclusions about the compliance of the caregivers both 
at the remote as well as at the tele- ICU. Unusual durations 
or timings of telemedical ward rounds will be reported 
to the clinical lead of the tele- ICU. In case of problems, 
tele- ICU consultants will contact remote ICU physicians 
via telephone.
Study outcomes and data collection schedule
Primary outcomes
To evaluate whether the intervention has a beneficial 
effect compared with usual care in at least one of the eight 
patient- level QIs in intensive care medicine (definition 
according to Kumpf et al38), eight co- primary binary effi-
cacy outcome measures derived from several QI- related 
performance parameters are prespecified (table 1), with 
each one of these defined as follows:
 ► Adherence (fulfilled yes/no) to a single intrahospital 
QI being daily assessed on a patient level starting from 
date of enrolment (after ICU admission) until ICU 
discharge, within a 24- hour time window.
Whether a single QI for patient i on day t is fulfilled or 
not is subsequently assessed by an intensive care specialist 
at the tele- ICU cockpit rating the underlying electronic 
QI documentation recorded by the remote site physician. 
This central endpoint adjudication process is used irre-
spective of whether the ICU delivers care on control or 
intervention condition.
Secondary outcomes
Secondary outcomes will be assessed during the sustain-
ment phase with time points scheduled 3 and 6 months 
after the patient’s exposure during index ICU stay. In 
particular, several key secondary outcomes are defined 
following the conceptual framework of core outcome sets 
with respect to PICS- related domains.10 46 Besides, some 
measures related to healthcare utilisation and socioeco-
nomic status will be assessed. A list of secondary outcomes 
and corresponding measurement instruments is provided 
in table 2.
Data collection and trial procedures during ICU stay and follow-up
Table 3 shows the patient data collection schedule.
ICU stay
Data documented by local research teams for all patients 
while at ICU include:
 ► Patient details (distinct identifiers, sociodemo-
graphics, statutory health insurance status).
 ► Baseline data and critical illness characteristics (eg, 
date and mode of hospital or ICU admission or transfer 
from general ward care, eligibility criteria, vital signs, 
laboratory findings, documented preexisting condi-
tions/medical history, illness severity scores).
 ► QI- related performance parameters assessed during 
daily QI visits.
 ► Hospital discharge data (discharge status (interme-
diate care/normal care/death), date of discharge/
death).
Follow-up procedures and post-acute care
In providing written informed consent, all patients assent 
to the study team having access to their medical records 
for data collection and to be contacted in order to arrange 
two follow- up visits. These are scheduled 3 and 6 months 
after index ICU discharge including an enhanced patient 
monitoring with the opportunity for on- demand counsel-
ling sessions between the treating GP or the rehabilita-
tion facility and investigators of the Charité experienced 
in ICU aftercare including PICS. These investigators of 
the Charité cannot be blinded regarding the treatment 
condition as they need to assess the electronic medical 
record data, which might be a potential source of bias. 
Locating of patients will contemporaneously be supported 
by contacting the patient’s GP starting after 1 month, 
providing information about the ERIC project and rele-
vant post- ICU follow- up procedures. If no GP is available 
or if the patient’s GP does not support the project, site 
personnel affiliated to the Charité (consortium leader) 
or to a consortium partner (Ernst von Bergmann hospital 
in Bad Belzig, Brandenburg) will conduct the follow- up 
assessments. The latter one is specialised for out- of- 
hospital mechanical ventilation and prolonged weaning 
in the case the patient stays at a rehabilitation facility, 
weaning unit or a hospital at the time of the follow- up 
visits. Depending on the patient’s health status, follow- up 
visits can be performed as home visits by clinicians of the 
study team.
Post- ICU follow- up data include health service and 
resource use assessed by means of medical records and 
will be documented by paper- based case report forms 
(CRFs) delivered to the patient’s GP or filled by the 
study team. Additionally, validated tests and patient 
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questionnaires with a focus to screen for PICS- related 
symptoms will be used (see table 2 for measurement 
instruments). Survival status at 3 and 6 months will be 
ascertained through the patient’s surrogates, the GP or 
caregivers, or municipal personal records database.
Data management, data security and quality control
Patient- level study data documented during the ICU 
stay will be collected and managed using Research Elec-
tronic Data Capture (REDCap) hosted at Charité at 
the site of the coordinating investigator. REDCap is a 
secure, web- based research data management platform 
providing (1) an intuitive interface for validated data 
entry; (2) audit trails for tracking data manipulation 
and export procedures; (3) automated export proce-
dures for seamless data downloads to common statistical 
packages and (4) procedures for importing data from 
external sources.47 Follow- up data at month 3 and 6 are 
initially collected via paper- based CRFs and question-
naires before being entered into a separate REDCap 
CRF. All installations have been made in compliance 
with EU General Data Protection Regulation (GDPR) 
and are continuously monitored by the data protection 
officers.
Data quality control will be assured by automated 
data entry plausibility checks, and on- site monitoring to 
ensure accuracy and enquire implausible or missing data 
on a regular basis.
Patient and public involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for participant recruitment, or the 
design and implementation of the study. A patient repre-
sentative is a member of the trial oversight committee 
(independent advisory board).
Table 2 Key secondary outcomes
Domain/outcome Timepoint Measurement instrument
All- cause mortality Up to 6 months after 
index ICU admission
Number of deaths from any cause including in- hospital mortality (using hospital 
administrative records, electronic medical records, municipal personal records 
database and the 3- month and 6- month follow- up with surrogates)
Mental health condition
Subdomains: anxiety and 
depression
At month 3 and 6 Patient- reported symptom burden on anxiety and depression assessed by the 
paper- based Patient Health Questionnaire-4 (screening tool). Higher scores 
indicate higher impairment60
Mental health condition
Subdomain: post- traumatic stress 
disorder (PTSD)
At month 6 Patient- reported symptom burden on PTSD assessed by the paper- based 
questionnaire Impact of Event Scale—Revised. Higher scores indicate greater 
distress61
Cognition
Subdomains: memory, visuospatial 
and visuoconstructional skills
At month 3 and 6 Functional outcome assessed by the MiniCog test (two tests: three- item recall 
task; clock- drawing task). Higher scores indicate better cognitive functioning62 63
Cognition
Subdomain: verbal fluency




At month 3 and 6 Patient’s walking ability and risk of fall assessed by the Timed Up and Go Test. 
Higher scores indicate higher impairment65
Physical function
Subdomain: muscle strength
At month 3 and 6 Patient’s muscle and nerve function assessed by the Hand- Grip- Strength Test 
measured with a dynamometer (average strength (in kg) of three trials for the 
dominant hand)66
Health- related quality of life 
(HRQoL)
At month 3 and 6 Patient’s self- reported HRQoL assessed by the EuroQol—5 dimensions—5 level 
descriptive system (items: mobility, self- care, usual activities, pain/discomfort, 
anxiety/depression), and the Visual Analogue Scale, a thermometer- like rating 
scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health 
state). Higher scores indicate better HRQoL67 68
Organ dysfunction At month 3 and 6 Number of patients with organ dysfunction as assessed by general practitioner or 
study personnel/ investigator
Pulmonary function and 
symptoms—dyspnoea
At month 6 Self- perceived breathlessness during daily activities graded by the Modified British 
Medical Research Council Dyspnea Scale (range 0–4). Higher score indicate 
higher impairment69 70
Outpatient ventilation Up to 6 months after 
index ICU discharge
Total duration (in days) of mechanical ventilation
Functioning and disability At month 6 Patient- reported General Disability Score, as measured by the WHO Disability 
Assessment Schedule V.2.0 for activity limitation and participation restriction, 12- 
item short version, self- administered questionnaire. The raw score is calculated by 
summing the values for each item. Higher scores indicate greater disability71 72
ICU and hospital length of stay At month 6 Total number of days spent at ICU, and in hospital
Employment status At month 3 and 6 Return to work, or change in employment status
ICU, intensive care unit.
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Table 3 Schedule of enrolment, interventions and assessments in the Enhanced Recovery after Intensive Care Trial from the 




transfer from ward) Treatment period Post- ICU follow- up*
To ICU ICU stay ICU discharge 3 months after T0 6 months after T0
Timepoint T-1† Tx T0 T1 T2
Randomisation—institutional level X         
Enrolment           
  Eligibility screen X         
  Patient‘s informed consent‡ X         
  Patient demographics X         
  Medical history, comorbidities at 
admission
X         
  Critical illness characteristics (eg, 
admission diagnosis, physiological 
and illness severity scores)
(X) X (X)     
Intervention          
  Intervention condition           
  Control condition (usual care)           
Assessments (in- person, by GP or site personnel)       
  Quality measurements (QI- related 
performance parameters, QI 
adherence (see table 1))
(X) X (daily) (X)     
  Mental health (Patient Health 
Questionnaire-4, Impact of Event 
Scale—Revised)§
      X X
  Cognition (MiniCog test, Animal 
Naming Test)§
      X X
  Physical and muscle function and 
symptoms (Timed Up and Go Test, 
Hand Grip Strength Test)§
      X X
  Health- related quality of life 
(EuroQol—5 dimensions—5 level)
      X X
  Organ dysfunction       X X
  Pulmonary function (Modified 
British Medical Research Council)
        X
  Outpatient ventilation       X X
  Functioning and disability (WHO 
Disability Assessment Schedule 
V.2.0)
        X
  All- cause mortality   X X X X
  Socioeconomic data (including 
educational background, current 
employment status/working ability)
      X   
  Healthcare utilisation, including 
concomitant (drug and non- drug) 
therapies, readmission, outpatient 
care
      X X
(X) depicts an optional measurement.
*Follow- up visits (at the GP’s practice, or at the patient’s home, or at a rehabilitation or nursing facility with assessments performed by site personnel) 
scheduled 3 and 6 months after the first study- related ICU discharge (index ICU stay).
†Time of admission to the hospital and to the ICU can be identical (depending on the patient’s health condition). Otherwise, transferral from hospital’s 
general ward to the participating ICU and recruitment happens at a later date.
‡If applicable, by authorised representative.
§Assessments are part of the outpatient post- intensive care syndrome screening.
GP, general practitioner; ICU, intensive care unit; QI, quality indicator.
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Public involvement is achieved through the active role of 
the German statutory health insurance company BARMER 
that represents the interests of its members. The results 
of the study will be disseminated to the patients through 
public information such as the BARMER customer maga-
zine and by the dedicated project’s website, which has a 
section for patients and relatives. Furthermore, our aim 
is to include patients in the interpretation of the study 
results if possible.
Clinical evaluation: statistical methodology and planned 
analyses
Power considerations and pretrial sample size calculation
Following the cluster- randomised design, a pragmatic 
power calculation was performed on a per hospital 
facility basis assuming equal cluster sizes and consid-
ering a limited number of potential sites and resources. 
To allow for eight binary co- primary outcomes with all of 
them having equal importance from a clinical perspec-
tive, a Bonferroni correction for multiple testings was 
applied for sample size calculation based on an overall 
one- sided type I error rate of alpha=5% (resulting in 
an alpha/8=0.625% significance level for confirmatory 
testing for a single QI). A minimum clinically relevant 
difference of 10% in QI adherence was specified; this 
target difference between both treatment conditions was 
guided by values in the literature.19 48
A two group χ2 test with a 0.625% one- sided 
significance level will have 82% power to detect the 
difference between a group 1 proportion (control 
condition), p1, of 60% and a group 2 proportion 
(intervention condition), p2, of 70% (OR of 1.556) 
when the sample size on each treatment condition is 
530 patients in the case of independent observations 
(nQuery Advisor V.7.0). To deal with the correlation 
between individuals from the same cluster, a design 
effect (variance inflation factor) of 1.35 was estimated, 
together with an intracluster correlation coefficient 
of 0.117 (derived from unpublished data available 
for site Charité only) which measures the correlation 
between observations within the same cluster.49 50 The 
total study sample size required for the CRT design is 
then obtained as 1431 patients. Considering practical 
aspects of admission and capacities results in a total 
setting of 12 clusters with approximately 163 cases per 
cluster and a total sample size of 1956 cases (12·163). 
Further details are given in the online supplemental 
file 4.
No transition period was included in the sample size 
calculation. Besides, there has been no allowance for 
varying cluster sizes since these methodological issues still 
need development for studies with stepped wedge design. 
Altogether, we expect the underlying assumptions used 
for the initial sample size calculation being rather conser-
vative to detect an absolute increase in adherence of 10% 
in at least one of eight QIs.
Statistical methods: clinical effectiveness
The analyses of primary outcomes will be conducted 
according to intention- to treat and clusters will 
be considered exposed to the intervention post 
randomised crossover date. All patients from a 
randomised medical facility defined as a unit of rando-
misation (one cluster comprising of one to three 
ICUs) who are recorded in the database and for whom 
at least one QI measurement has been obtained will be 
included in the analyses with respect to the treatment 
specified by the allocated randomisation order. The 
eight co- primary outcomes will be compared using 
Bonferroni- adjusted two- sided confirmatory testing at 
a 0.625% significance level.
Medical facilities who initially agreed to participate but 
subsequently withdraw before trial start date but after 
randomisation (without recruiting any patients) will 
be excluded. Several protocol deviations at the cluster 
level may occur: Departures from the randomisation at 
a cluster level are defined as any cluster, which does not 
switch to the intervention at the assigned intervention 
implementation time point according to the randomisa-
tion schedule determined prior to trial commencement. 
Depending on the relevance and number of the devia-
tions, a per- protocol analysis, which will exclude depar-
tures from the randomisation schedule (including the 
affected patients), will be completed for the primary effi-
cacy outcomes only.
Most patients experience either the control or inter-
vention condition during their index ICU stay (defined as 
the first study- related ICU stay at one of the participating 
medical facilities). ‘Crossover patients’, that is, patients 
being exposed to both conditions, should be avoided in 
the case they are admitted to the ICU shortly before the 
allocated crossover date. If a patient will be readmitted to 
the ICU at a later time—documented as a new case—he 
or she will be exposed to the condition delivered at the 
respective time point which might be different from the 
one during index ICU stay.
To avoid (within cluster) contamination, patients who 
will be enrolled before the ICU’s crossover with set- up 
and activation of the tele- ICU will remain being treated 
on control condition according to the protocol. There-
fore, patients who will nevertheless be exposed to both 
conditions due to being enrolled immediately before the 
ICU’s crossover will be excluded from the analyses (ie, 
from the primary comparison of control and interven-
tion condition).39 Likewise, patients who are admitted on 
control and later readmitted on intervention condition 
after a site’s crossover, thus, being exposed to both condi-
tions, will also be excluded from the principal analysis to 
assess telemedicine effectiveness.
A generalised linear mixed effects modelling approach 
is chosen that allows to model intervention- by- time inter-
actions as well as to consider assumptions on effects 
regarding the transition periods. Related sensitivity anal-
yses will be described in the upcoming statistical analysis 
plan (SAP). More details on the models for primary and 
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secondary outcomes are described in the online supple-
mental file 4. There, we also discuss methodological issues 
related to death truncation and informative missings for 
functional patient outcomes.
Statistical analyses will be performed using the software 
package R V.3.6.1 or higher.51 A full SAP will be written 
ahead of the final database lock.
Process evaluation
To ensure that the intervention is delivered as expected 
and successfully implemented, selected key components 
will be evaluated. There will be a nested qualitative study 
embedded within this SW- CRT to assess the acceptability 
of e- learning courses during the training phase. For tele-
medical ward rounds (QI visits), data on the connection 
failure rate and overall connection quality between the 
tele- ICU and remote ICUs are closely monitored to avoid 
inadequate implementation of the intervention.
Health economic evaluation
Alongside the main trial, a health economic evaluation 
will be performed to assess the economic impact of the 
ERIC intervention compared with standard of care.52 53 
This evaluation consists of cost- effectiveness analyses and 
a cost- utility analysis,54 and the perspective of the health, 
long- term and retirement insurances will be taken into 
account.55 Direct medical and non- medical costs as well 
as indirect costs and outcomes will be assessed for the 
ICU and post- ICU period up to 12 months (by extrap-
olation).56 Further, all costs and consequences will be 
discounted by 3%, as recommended by the Institute for 
Quality and Efficiency in Healthcare (IQWiG).57 58 Health 
economic outcomes include mortality rate, rate of long- 
term mechanically ventilated patients, QoL as measured 
by EuroQol—5 dimensions—5 level and quality- adjusted 
life years gained.56 59
The following data sources will be used, among others, 
to estimate costs and outcomes: clinical data collected 
during ICU stay, hospital claims data, statutory health 
insurance expenditures data (BARMER) and data 
captured from the CRF used for follow- up assessments. 
The results will be reported as mean costs, mean outcomes 
and incremental cost- effectiveness ratios, where appro-
priate. Robustness will be addressed in sensitivity analyses, 
as suggested by IQWiG.58 ERIC will be shown to be cost- 
effective if costs are lower and outcomes are the same or 
better, or if costs are the same and outcomes are clearly 
better as compared standard of care.
DISCUSSION AND PRACTICAL IMPLICATIONS
Study impact and importance
ERIC is a German large- scale cluster randomised trial with 
a stepped wedge design evaluating whether the phased 
implementation of a ‘round and response’ telehealth 
programme is effective. In doing so, it is hypothesised 
that daily telemedicine- based, structured ward rounds 
being one of the core interventional components can 
be a successful performance- improvement strategy not 
only on the institutional level (clinician- led QIs as surro-
gates for quality of care at ICUs), but also on the level of 
the critically ill patient (benefit on patient- centred core 
outcomes, in particular with respect to PICS).
Given the significant financial and personnel resources 
required for the installation and upkeep of telemedicine 
systems at ICUs, a thorough evaluation of the impact of a 
tele- ICU coverage leading to improved intensivist coverage 
at off- site hospitals is vital. Assessing the process quality at 
ICU imposes the risk of an inadequate choice of QIs. The 
QIs chosen for this trial were established by the DIVI in 
2010, and are evidence- based, clinical- practice guideline 
derived, and operationalised ensuring that they can be 
measured on a daily basis. Eight (out of ten) consensus- 
based QIs are specified as binary primary outcomes, which 
can be reliably assessed on the patient level. However, this 
results in eight possible trial outcomes increasing the possi-
bility of an equivocal rather than a definitive result.
PICS- related, patient- centred outcomes such as quality 
of life will be assessed 3 and 6 months but not at baseline, 
that is, before ICU admission. However, given the large 
sample size, we assume that randomisation will balance 
the baseline levels of these secondary outcomes.
Conclusion
ERIC is one of the first projects of the German Innova-
tion Fund’s ‘New Forms of Care’ programme. The project 
was assessed as evidence based and regionally viable. The 
evaluation concept is robust and has been developed with 
clinicians, biometricians and health economists. It will 
allow a comprehensive assessment from the patient’s, clin-
ical and health economic perspective after about 3 years.
If this trial demonstrates a beneficial impact on evidence- 
based QIs at ICU, alongside a favourable health economic 
assessment, then there would be a strong case for incorpo-
rating this telemedicine programme into clinical routine 
throughout Germany—leading to a system change in crit-
ical care medicine by improving patient care pathways.
TRIAL STATUS
At the time of first manuscript submission, research ethics 
approval has been obtained for the trial. Data collec-
tion with enrolment of the first patient commenced on 
04 September 2018. Last patient last visit (including a 
6- month follow- up period) is expected in October 2020.
Progress of the study and extension of the study duration
Before the transition of the last sequence group from 
control to intervention status, we realised that the 
preplanned target sample size could not be reached since 
the recruitment rate was far lower than anticipated. Addi-
tionally, barriers with respect to data protection rules were 
identified leading to a delayed cooperation agreement 
between several participating sites and the consortium 
leader. This in particular affected the number of patients 
recruited under control condition. One cluster of sequence 
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group three withdrew informed consent prior to start of 
recruitment. In May 2019, all consortium partners agreed 
to extend the duration of the recruitment (first patient in 
to last patient in) from 12 to 19 months and postponed 
the prespecified third crossover date (while extending the 
rollout period) by 3 months to further enhance the number 
of patients treated on control condition.
ETHICS AND DISSEMINATION
Ethical considerations
This study is being conducted in accordance with ethical 
principles that have their origin in the Declaration of 
Helsinki and is consistent with Good Clinical Practice 
(GCP). Enrolment of patients at the participating ICUs did 
not start until the written and unrestricted positive vote of the 
local ethics committee (EC) was obtained. The protocol is 
based on the underlying project application which received 
previous independent peer review as part of the grant 
funding process. Together with the patient information 
sheets and consent forms, the protocol was first approved 
by the EC of the Charité—Universitätsmedizin Berlin on 
26 January 2018 (approval number EA1/006/18), and the 
EC of the Brandenburg Medical School Theodor Fontane 
joined (approval number Z-01-20180828). Amendments to 
the protocol will be submitted to the EC for review. Indi-
vidual written informed consent including consent to data 
collection will be obtained from all eligible patients in the 
trial. Consent forms for the trial include consent for publi-
cation of results in peer- reviewed journals. Relevant data 
protection rules for all analysed data will be enforced.
By implementing a quality improvement interven-
tion based on evidence- based QIs, no additional risks 
to patients are expected relative to standard of care. 
Outcome data are routinely collected health data together 
with post- ICU data. Therefore, adverse events will not be 
monitored or reported. An independent Advisory Board 
has been appointed to ensure that ethical, legal and social 
aspects and responsibilities are carried out according to 
GCP.
Dissemination plan
The success of the trial will depend entirely on the collab-
oration of clinicians in the participating ICUs and those 
who hold key responsibilities at the study sites. The main 
results of the evaluation will be reported to trial collab-
orators and subsequently be published in peer- reviewed 
scientific journals and at national and international 
conferences. Additionally, study findings will be dissem-
inated via a press release that will also be available on 
social media after publication to reach out to patients and 
surrogates as well as healthcare professionals. Authors 
and collaborators will be involved in reviewing drafts of 
the manuscripts, press releases and any other publication 
format arising from this project.
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